Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma

Published:2021-05 Issue: Volume: Page:
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Gorin Michael A.,Patel Hiten D.,Rowe Steven P.,Hahn Noah M.,Hammers Hans J.,Pons Alice,Trock Bruce J.,Pierorazio Phillip M.,Nirschl Thomas R.,Salles Daniela C.,Stein Julie E.,Lotan Tamara L.,Taube Janis M.,Drake Charles G.,Allaf Mohamad E.

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference10 articles.

1. Immune checkpoint blockade in renal cell carcinoma;Rappold;J Surg Oncol,2021

2. The current role for adjuvant and neoadjuvant therapy in renal cell cancer;Gleeson;Curr Opin Urol,2019

3. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?;Patel;Future Oncol,2019

4. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy;Labbate;J Immunother Cancer,2019

5. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma;Singla;Urol Oncol,2019

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study;The Lancet Oncology;2024-08

2. Perioperative immunotherapy in renal cell carcinoma;The Lancet Oncology;2024-08

3. A Narrative Review on Systemic Therapy for Renal Cell Carcinoma in the Perioperative Setting;Journal of Urologic Oncology;2024-07-31

4. Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression;Cancer Letters;2024-07